{"entity":{"id":"nct04416516","kind":"trial","name":"Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor","aka":[],"tldr":"A phase 2 trial of SP-002 run by Ascend Biopharmaceuticals Ltd, completed.","summary":"Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor is a phase 2 interventional study registered as NCT04416516 by Ascend Biopharmaceuticals Ltd, with 21 participants enrolled, started 2020-07-16. Conditions recorded: Basal Cell Carcinoma and Basal Cell Nevus Syndrome. Interventions recorded: ASN-002.","status":"completed","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT04416516","url":"https://clinicaltrials.gov/study/NCT04416516"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["basal-cell-carcinoma"],"sections":[],"technologies":[],"targets":[],"drugs":["sp-002"],"companies":["stamford-pharmaceuticals"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04416516","phase":"2","setting":"A Phase 2A Study to Assess the Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor in the Treatment of Multiple Low Risk Basal Cell Carcinomas in Sporadic or Basal Cell Nevus Syndrome Patients","sponsor":"Ascend Biopharmaceuticals Ltd","enrolled":21,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04416516/","neighbours":{"cancer":[{"id":"basal-cell-carcinoma","kind":"cancer","name":"Basal cell carcinoma","route":"/cancers/basal-cell-carcinoma/"}],"drug":[{"id":"sp-002","kind":"drug","name":"SP-002","route":"/drugs/sp-002/"}],"company":[{"id":"stamford-pharmaceuticals","kind":"company","name":"Stamford Pharmaceuticals","route":"/companies/stamford-pharmaceuticals/"}]}}